Sartorius Stedim Biotech

Discover how Sartorius AG is driving 8‑11% organic growth, boosting biopharma tech from R&D to scale‑up, and selecting strategic single‑use acquisitions for the future of biologics.

Discover Sartorius Stedim Biotech’s 2025 URD and 2026 financial calendar: audited 2025 results, upcoming earnings dates, and investor‑focused insights.

Discover how Sartorius Stedim Biotech’s AI‑enabled lab equipment powers drug‑discovery outsourcing, driving growth with GMP‑grade solutions for pharma R&D.

Sartorius Stedim Biotech’s stock price has fluctuated within a 52-week range, with a current price of 170 EUR and potentially high valuation metrics.

Sartorius Stedim Biotech is a strong buy opportunity, with 80% of analysts recommending a purchase and a potential for growth of over 20%.

Sartorius Stedim Biotech has reported significant growth in its quarterly earnings, driven by strong performance across various industries and a positive outlook for 2025.

Sartorius Stedim Biotech has delivered a record-breaking first half, exceeding expectations with a 19.3% growth in underlying EBITDA and a 9.4% increase in sales revenue.

Sartorius Stedim Biotech has partnered with Sensible Biotechnologies to enhance its mRNA design and manufacturing capabilities and scale up its cell-based technology platform.

Sartorius Stedim Biotech has released financial updates, including a new high stock price and a liquidity contract, indicating a stable and active market for its shares.

Sartorius Stedim Biotech’s share price remains stable, with a solid financial foundation and ability to adapt to changing market conditions, despite a notable increase in shares held by Kepler Cheuvreux.